Similar articles

• Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.

  Pasmantier MW, Coleman M, Silver RT, Ballard WP. Pasmantier MW, et al. Cancer Treat Rep. 1985 Jun;69(6):689-93. Cancer Treat Rep. 1985. PMID: 3926310
• Complete remission at laparotomy: still a gold standard in ovarian cancer?

  Neijt JP, ten Bokkel Huinink WW, Van der Burg ME, van Oosterom AT. Neijt JP, et al. Lancet. 1986 May 3;1(8488):1028. doi: 10.1016/s0140-6736(86)91290-0. Lancet. 1986. PMID: 2871299 Clinical Trial. No abstract available.
• Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.

  Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Pinedo HM. Neijt JP, et al. Radiother Oncol. 1984 Jun;2(1):19-29. doi: 10.1016/s0167-8140(84)80034-1. Radiother Oncol. 1984. PMID: 6438704
• Altretamine.

  Hansen LA, Hughes TE. Hansen LA, et al. DICP. 1991 Feb;25(2):146-52. doi: 10.1177/106002809102500209. DICP. 1991. PMID: 1905441 Review.
• The role of hexamethylmelamine in the management of ovarian cancer.

  Schein PS, Scheffler B, McCulloch W. Schein PS, et al. Cancer Treat Rev. 1991 Mar;18 Suppl A:67-75. doi: 10.1016/0305-7372(91)90026-v. Cancer Treat Rev. 1991. PMID: 1904311 Review.